Trials / Conditions / Relapsed/Refractory AML

Relapsed/Refractory AML

14 registered clinical trials studyying Relapsed/Refractory AML — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax NCT07471841	Timothy Pardee	Phase 2
Not Yet Recruiting	Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML NCT07026942	Nationwide Children's Hospital	Phase 1 / Phase 2
Active Not Recruiting	Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS NCT06846606	Auron Therapeutics, Inc.	Phase 1
Not Yet Recruiting	CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML NCT06763666	Nanfang Hospital, Southern Medical University	Phase 4
Active Not Recruiting	Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic N NCT06359002	Byondis B.V.	Phase 1
Unknown	Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients NCT05805072	The First Affiliated Hospital of Soochow University	N/A
Active Not Recruiting	A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard o NCT05428969	Faron Pharmaceuticals Ltd	Phase 1 / Phase 2
Terminated	Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AM NCT05054543	Apollomics Inc.	Phase 3
Completed	Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients NCT04839341	Apollomics Inc.	Phase 1
Active Not Recruiting	NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS NCT04623944	Nkarta, Inc.	Phase 1
Unknown	CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001) NCT03631576	Fujian Medical University	Phase 2 / Phase 3
Terminated	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies NCT02520427	Amgen	Phase 1
Completed	POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients NCT01319864	Seattle Children's Hospital	Phase 1
Completed	The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) NCT01258816	Clavis Pharma	Phase 1